GALMED PHARMACEUTICALS LTD (GLMD) Stock Price, Quote, News and Overview
NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD
GLMD Quote, Performance and Key Statistics
NASDAQ:GLMD (4/25/2025, 8:11:44 PM)
1.57
-0.05 (-3.09%)
The current stock price of GLMD is 1.57 USD. In the past month the price decreased by -6.55%. In the past year, price decreased by -66.59%.
GLMD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About GLMD
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Company Info
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 6
Company Website: https://www.galmedpharma.com
Investor Relations: http://galmedpharma.investorroom.com/
Phone: 97236938448
GALMED PHARMACEUTICALS LTD / GLMD FAQ
What is the stock price of GALMED PHARMACEUTICALS LTD today?
The current stock price of GLMD is 1.57 USD. The price decreased by -3.09% in the last trading session.
What is the ticker symbol for GALMED PHARMACEUTICALS LTD stock?
The exchange symbol of GALMED PHARMACEUTICALS LTD is GLMD and it is listed on the Nasdaq exchange.
On which exchange is GLMD stock listed?
GLMD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GALMED PHARMACEUTICALS LTD stock?
7 analysts have analysed GLMD and the average price target is 12.24 USD. This implies a price increase of 679.62% is expected in the next year compared to the current price of 1.57. Check the GALMED PHARMACEUTICALS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GALMED PHARMACEUTICALS LTD worth?
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 3.55M USD. This makes GLMD a Nano Cap stock.
How many employees does GALMED PHARMACEUTICALS LTD have?
GALMED PHARMACEUTICALS LTD (GLMD) currently has 6 employees.
What are the support and resistance levels for GALMED PHARMACEUTICALS LTD (GLMD) stock?
GALMED PHARMACEUTICALS LTD (GLMD) has a resistance level at 1.63. Check the full technical report for a detailed analysis of GLMD support and resistance levels.
Should I buy GALMED PHARMACEUTICALS LTD (GLMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GLMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GLMD, evaluating the profitability, health, valuation and growth aspects
- GALMED PHARMACEUTICALS LTD (GLMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GALMED PHARMACEUTICALS LTD (GLMD) Sales and EPS estimates to see what analysts future expectations are.
- GALMED PHARMACEUTICALS LTD (GLMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GALMED PHARMACEUTICALS LTD (GLMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- GALMED PHARMACEUTICALS LTD (GLMD) Stock Chart to make your own analysis
- GALMED PHARMACEUTICALS LTD (GLMD) Latest news and press-releases to stay up to date.
Does GALMED PHARMACEUTICALS LTD (GLMD) stock pay dividends?
GLMD does not pay a dividend.
When does GALMED PHARMACEUTICALS LTD (GLMD) report earnings?
GALMED PHARMACEUTICALS LTD (GLMD) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of GALMED PHARMACEUTICALS LTD (GLMD)?
GALMED PHARMACEUTICALS LTD (GLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.12).
What is the Short Interest ratio of GALMED PHARMACEUTICALS LTD (GLMD) stock?
The outstanding short interest for GALMED PHARMACEUTICALS LTD (GLMD) is 3.06% of its float. Check the ownership tab for more information on the GLMD short interest.
GLMD Technical Analysis
GLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLMD. The financial health of GLMD is average, but there are quite some concerns on its profitability.
GLMD Financial Highlights
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -39.12. The EPS increased by 68.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.63% | ||
| ROE | -46.04% | ||
| Debt/Equity | 0 |
GLMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GLMD. The Buy consensus is the average rating of analysts ratings from 7 analysts.